Investor Alert

New York Markets After Hours

Dec. 14, 2020, 4:36 a.m. EST

CDK 4/6 Inhibitor Drugs Market: Future Forecast Assessed On The Basis Of How the Market Is Predicted to Grow Till 2028

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Merck & Co. Inc. (MRK)
  • X
    Eli Lilly & Co. (LLY)
  • X
    Johnson & Johnson (JNJ)

or Cancel Already have a watchlist? Log In

Dec 14, 2020 (AmericaNewsHour) -- Research Nester released a report titled "CDK 4/6 Inhibitor Drugs Market: Global Demand Analysis & Opportunity Outlook 2028" which delivers detailed overview of the global CDK 4/6 inhibitor drugs market in terms of market segmentation by product type, route of administration, distribution channel and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter's five force model.

CDK4/6 inhibitors restrict signals that stimulate the proliferation of cancerous cells at an early stage. Owing to its wide-scale application for the treatment of metastatic breast cancer, the CDK 4/6 inhibitor drugs market is anticipated to record a significant CAGR over the forecast period, i.e., 2020-2028. The market is segmented by end user into hospitals, clinics, research laboratories and retail pharmacies, out of which, the segment for hospitals is anticipated to hold the leading share in the CDK 4/6 inhibitors market. This can be attributed to its wide availability of CDK 4/6 inhibitor drugs which are used for the patient's treatment only at the hospital under the doctors' supervision.

Based on the regional analysis, the CDK 4/6 inhibitor drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market for CDK 4/6 inhibitor drugs in North America is predicted to hold the highest share in the market on account of favourable reimbursement policies by the government and presence of prominent market players in the region which manufacture and market CDK 4/6 inhibitor drugs.

Download Sample of This Strategic Report @ https://www.researchnester.com/sample-request-2533

Increasing Incidence Rate Of Breast Cancer To Boost The Market Growth

According to the World Cancer Research Fund (WCRF), breast cancer is the most commonly occurring cancer in women and there were over 2 million new cases in 2018. 

The probability that a woman will die from breast cancer is 1 in 38 (about 2.6%),as per the data provided by American Cancer Society.

The demand for CDK 4/6 inhibitor drugs is high as the rate of breast cancer among women is constantly increasing. Further, breast cancer is the leading cause of cancer-related deaths in women. Additionally, the huge investment in healthcare infrastructure is anticipated to increase the market growth of CDK 4/6 inhibitor drugs over the forecast period. However, the high cost of the drugs involved in the treatment of cancer coupled with the side-effects of inhibitor drugs is estimated to hamper the market growth.

This report also provides the existing competitive scenario of some of the key players of the global CDK 4/6 inhibitor drugsmarket which includes company profiling ofPfizer Inc., Novartis AG (swx:NOVN), Sanofi (epa:SAN), Merck & Co., Inc. /zigman2/quotes/209956077/composite MRK +0.06% , F.Hoffmann-La Roche Ltd. (swx:RO), Beacon Pharmaceuticals Ltd., Eli Lilly and Company /zigman2/quotes/200106384/composite LLY -0.63% , Johnson & Johnson Services, Inc. /zigman2/quotes/201724570/composite JNJ +0.44% , Bristol-Myers Squibb Company /zigman2/quotes/202559280/composite BMY -0.28% and AstraZeneca /zigman2/quotes/203048482/delayed UK:AZN +1.76% .

Curious about this latest version of report? Obtain Report Details @ https://www.researchnester.com/reports/cdk-46-inhibitor-drugs-market/2533

The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global CDK 4/6 inhibitor drugsmarket that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

About Research Nester

Research Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives for their future investment while avoiding forthcoming uncertainties. With an out-of-the-box mindset to produce statistical and analytical market research reports, we provide strategic consulting so that our clients can make wise business decisions with clarity while strategizing and planning for their forthcoming needs and succeed in achieving their future endeavours. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds.

Contact Us

AJ Daniel
Email: info@researchnester.com
U.S. Phone: [+1 646 586 9123]
U.K. Phone: [+44 203 608 591]

The post CDK 4/6 Inhibitor Drugs Market: Future Forecast Assessed On The Basis Of How the Market Is Predicted to Grow Till 2028 appeared first on America News Hour .


Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

$ 71.97
+0.04 +0.06%
Volume: 11.99M
Sept. 21, 2021 4:02p
P/E Ratio
Dividend Yield
Market Cap
$182.08 billion
Rev. per Employee
$ 230.17
-1.47 -0.63%
Volume: 2.15M
Sept. 21, 2021 4:03p
P/E Ratio
Dividend Yield
Market Cap
$221.58 billion
Rev. per Employee
$ 164.53
+0.72 +0.44%
Volume: 6.04M
Sept. 21, 2021 4:00p
P/E Ratio
Dividend Yield
Market Cap
$431.23 billion
Rev. per Employee
$ 60.33
-0.17 -0.28%
Volume: 8.80M
Sept. 21, 2021 4:00p
P/E Ratio
Dividend Yield
Market Cap
$134.44 billion
Rev. per Employee
UK : U.K.: London
8,710.00 p
+151.00 +1.76%
Volume: 2.03M
Sept. 21, 2021 4:35p
P/E Ratio
Dividend Yield
Market Cap
£132.59 billion
Rev. per Employee

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.